Bitmine Immersion Technologies disclosed that its total crypto, cash, and marketable securities holdings have reached $17.4 billion, including 6.02 million ETH tokens. The company now owns 4.9% of the total ETH supply and reported that its MAVAN staking platform currently has 5.07 million staked ETH. Additionally, the company highlighted its $117 million stake in Eightco Holdings and its recent addition to the Russell 1000 Large-cap index.
Pagaya Technologies provided a historical performance and portfolio quality update for its personal loan and auto loan networks as of July 2026. The data highlights a personal loan portfolio with a 662 weighted average credit score and an auto portfolio with an 18% weighted average coupon. This disclosure provides investors with granular credit metrics across multiple vintages to demonstrate the stability of the company's AI-driven underwriting network.
InTest Corporation announced preliminary results for Q3 2026, expecting record orders between $48 million and $50 million and revenue at the high end of its $33 million to $35 million guidance range. The performance was driven by record back-end semiconductor orders fueled by AI-driven data center demand, resulting in an estimated backlog of $58 million to $60 million.
DeFi Development Corp. reported that its Solana (SOL) treasury grew to approximately 2.56 million SOL as of October 2, 2026, representing an 11% increase since August 12. Preliminary Q3 estimates indicate double-digit growth in SOL per share and over 100% growth in NAV per share, driven by continued SOL accumulation and the deployment of its CHAD preferred stock dividend strategy.
Stablecoin Development Corporation provided a preliminary update on its digital asset holdings and balance sheet for the quarter ended September 30, 2026. The company reported holding approximately 2.32 billion SKY tokens with a fair value of $180.2 million and a cash balance of $7.2 million. The update highlights the company's ongoing strategy of staking SKY tokens within the Sky Protocol, earning 34.6 million tokens in rewards during the quarter.
Rezolute announced that the FDA recommended a pre-BLA meeting for ersodetug in congenital hyperinsulinism (HI) following a review of Phase 3 sunRIZE data. Although the trial missed its primary and key secondary endpoints, the Agency encouraged the meeting as a precursor to a potential Biologics License Application (BLA) submission. The company is also awaiting Phase 3 upLIFT results in tumor HI this quarter to finalize its overall regulatory strategy.
Counterparty
FDA
“We appreciate FDA’s thorough review of the extensive body of data generated in sunRIZE and are encouraged by the Agency’s recognition that this data will require in-depth evaluation during a formal BLA review.”
Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute
Strive, Inc. provided an operational update disclosing that it purchased 2,000 bitcoin between September 28 and October 2, 2026, at an average price of $84,422 per bitcoin. As of September 30, 2026, the company held 28,000 bitcoin with a fair value of approximately $2.34 billion and total treasury value of $2.68 billion. The filing also updated the company's cash position and share counts for its Class A, Class B, and Series A Perpetual Preferred stock.
New Fortress Energy announced that its Fast LNG unit is currently offline due to a mechanical issue with the facility's gas turbine. The company is working with the turbine manufacturer for repairs and expects the unit to return to service during the fourth quarter of 2026.
Omega Healthcare Investors transitioned the operations of 32 skilled nursing facilities in Florida from Airamid Health Services to PACS Group. The transition is expected to increase annual rent by $26.1 million in the first year and $2.5 million in the second year, though Omega incurred a one-time expense of approximately $90 million to facilitate the move.
Artificial Intelligence Technology Solutions Business Update
Artificial Intelligence Technology Solutions' subsidiary, Robotic Assistance Devices (RAD), received a dditional orders for two RIO Mini security units and two TOM visitor management units form a longstanding global logistics client. The unnamed client has previously adopted various RAD solutions, including the ROAMEO autonomous patrol vehicle, to support security operations at existing facilities.
Deep Isolation Nuclear has received a drilling permit from the Texas Railroad Commission for its full-scale, non-radioactive Commercialization Pilot near Cameron, Texas. This regulatory milestone allows the project to advance from the engineering and design phase into construction and field activities, including drilling a new well in collaboration with Halliburton.
Ford reported third-quarter 2026 U.S. sales of 509,764 vehicles and provided an update on a short-term supplier issue that affected F-150 production at the end of September. The company reaffirmed its full-year 2026 adjusted EBIT guidance, stating the production impact is containable within the existing forecast.
Cycurion CEO L. Kevin Kelly participated in an interview to discuss the company's growth strategy, including a previously announced $54.6 million contract and the acquisition of Digital Ally's Video Solutions business. The company highlighted its pro forma gross revenue run rate of approximately $30 million and its expansion into the public safety and federal cybersecurity markets.
Tesla reported its Q3 2026 operational metrics, producing 464,391 vehicles and delivering 486,532 vehicles. The company also deployed 13.7 GWh of energy storage products during the quarter. Formal financial results, including net income and cash flow, are scheduled to be released on October 21, 2026.
Freeport-McMoRan provided a Q3 2026 operational update reporting consolidated copper production of 830 million pounds and gold production of 230 thousand ounces, both in line with expectations. Gold sales were lower than estimated due to the deferral of 60,000 ounces of refined gold at PT Freeport Indonesia to the fourth quarter. The company also noted that PTFI’s smelter in Eastern Java successfully re-commenced operations in late August 2026 following a prior suspension.
Blue Owl Technology Income Corp. (OTIC) provided a shareholder update reporting a 2.1% quarter-to-date total return for Class I shareholders as of August 31, 2026, and a 9.0% annualized total return since inception. The Fund noted stable credit quality with non-accruals at 0.3% of fair value and reported that estimated repurchase requests for the third quarter totaled $1.1 billion (39.0% of shares outstanding), which will be fulfilled on a 5% pro rata basis.
Blue Owl Credit Income Corp. provided an operational update reporting that it received $3.1 billion in share repurchase requests for Q3 2026, a decrease from previous quarters. The Fund will fulfill its 5% tender offer on a pro rata basis and highlighted its strong liquidity position of $11.2 billion and resilient credit quality with non-accruals at only 0.2% of fair value.
Rivian reported Q3 2026 production of 19,751 vehicles and deliveries of 19,248 vehicles from its Normal, Illinois facility. The company reaffirmed its full-year 2026 delivery guidance of 65,000 to 70,000 vehicles and scheduled its formal Q3 financial results release for October 29, 2026.
Integra LifeSciences announced preliminary Q3 2026 revenue of $410-$412 million and updated its full-year guidance to reflect a $22-$27 million total revenue impact from flooding at its Cincinnati manufacturing facility. The company expects the facility to return to full operations in Q2 2027 and anticipates insurance recoveries to mitigate a substantial portion of the financial impact.
BNB Plus Corp. announced a strategic transition from a passive digital asset treasury model to an operating company focused on institutional technology infrastructure for blockchain and AI. The company also plans to monetize its LineaRx subsidiary, which specializes in enzymatic DNA manufacturing for genetic medicines.
Agree Realty Corporation disclosed its weighted-average number of common shares outstanding for the three and nine months ended September 30, 2026. The filing provides specific share counts used for basic and diluted earnings per share calculations, including the dilutive impact of ATM and April 2025 forward equity offerings.
Cullinan Therapeutics has initiated a rolling New Drug Application (NDA) submission to the FDA for zipalertinib in combination with chemotherapy for first-line treatment of NSCLC with EGFR exon 20 insertion mutations. The submission is being conducted under the FDA's Real-Time Oncology Review (RTOR) program and is supported by positive Phase 3 REZILIENT3 trial data. Completion of the submission is expected by year-end 2026, potentially triggering a $100 million milestone payment from partner Taiho upon approval.
Forward Industries provided a quarterly update on its Solana (SOL) treasury strategy, reporting that it increased its holdings by 948,601 SOL to a total of 8.5 million SOL as of September 30, 2026. The company reported that its SOL per share grew 10.4% during the quarter (42% annualized) and provided a preliminary net asset value (NAV) calculation of approximately $870.4 million.
NexMetals Mining Corp. reported an updated Mineral Resource Estimate for its Selebi Main deposit in Botswana, showing a 72% increase in tonnage to 32.47 million tonnes. The update establishes 495,400 contained tonnes of copper and 316,800 contained tonnes of nickel, while a separate estimate for the Selebi North deposit remains in progress. This update incorporates new drilling data from the Flexure Zone and updated metal price assumptions.
“The updated Selebi Main estimate is a major milestone for NexMetals. Resource growth, driven primarily by new drilling in the Flexure Zone, exceeded our expectations and provides a stronger foundation for the next phase of technical work.”
Chemung Financial Corporation's wholly owned subsidiary, Chemung Canal Trust Company, has completed its conversion from a New York chartered trust company to a national bank. The bank will now operate as 'Chemung Canal Trust Company, National Association' and will be subject to supervision and regulation by the Office of the Comptroller of the Currency (OCC).
BioCardia has submitted a revised Pre-Submission to the FDA Center for Devices and Radiological Health (CDRH) for the approval of its Helix Catheter for therapeutic and diagnostic delivery to the heart. The submission incorporates prior FDA feedback regarding marketing clearance pathways and safety data, with the FDA expected to provide written feedback or hold a meeting within 70 days. An independent clearance would allow BioCardia to partner with other developers of cell, gene, and protein therapeutics requiring targeted cardiac delivery.
SINTX Technologies announced preliminary Q3 2026 revenue of $2.2 million, significantly exceeding its previous guidance of $0.9-$1.1 million due to strong industrial ceramics sales to Fortune 500 aerospace customers. The revenue milestone also triggers a call right for the company to require the exercise of outstanding Class B warrants, which could potentially raise up to $4.0 million in additional capital.
Capstone Holding Corp. reported preliminary operating results for July and August 2026, showing 7.6% organic revenue growth to $14.0 million and 6.5% organic gross profit growth to $3.5 million. The update highlights the company's capital-efficient growth strategy and plans for regional expansion in the Pacific Northwest and product diversification at Carolina Stone.
Casella Waste Systems announced that its NCES Landfill in Bethlehem, New Hampshire, will stop accepting municipal solid waste on December 31, 2026. This closure date is earlier than the previously expected end-of-2027 timeline due to updated evaluations of permitted airspace and fill rates. The company expects a higher level of landfill amortization expense in Q4 2026 as a result, though it does not anticipate a material impact on full-year financial results.
Orchestra BioMed exceeded its enrollment target for the BACKBEAT Global Pivotal Trial, randomizing 330 patients across 81 sites globally. The trial is evaluating AVIM Therapy for uncontrolled hypertension in pacemaker patients in collaboration with Medtronic. The company expects to submit primary endpoint data for presentation at a major cardiovascular conference in Q2 2027.